News

Study Shows Proof of Concept of BioIVT HEPATOPAC Cultures with Targeted Assay to Evaluate Bioactivation Potential and Drug-induced Liver Injury (DILI) Risk

New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment

Westbury, NY – Oct. 12, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).¹

Stevenage Bioscience Catalyst opens Spark Building to support Cell and Gene scale-up

Stevenage Bioscience Catalyst’s new Spark Building opened its doors in January to accommodate the rapid growth of scale-up businesses within Hertfordshire’s world-class cell and gene cluster.

Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance

Systematic direct cell conversion platform published in Cell Systems

Platform measures changes in H3K4me3 histone modifications to predict optimal growth factors required to both maintain cells in culture and support conversion between cell types

EpiMOGRIFY co-developed and co-owned by Duke-NUS, Monash University and Mogrify

Stevenage named High Potential Opportunity zone for Cell and Gene Therapy

The Department for International Trade (DIT) has classified Stevenage, Hertfordshire, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected to help attract further overseas investment into the county.

TTP Ventus and Sensirion collaborate on high-performance microfluidic driver

• TTP Ventus Disc Pump combined with Sensirion liquid flow sensor

• Together, technologies provide exceptional liquid flow control

• New system suitable for laboratory testing and product prototyping

October eNews 2020

Click here for the October edition of eNews.

Ground-breaking cancer diagnostics spin out that looks to save up to 2,000 lives each year joins Newcastle Helix eco-system

The Biosphere, a specialist lab facility on Newcastle Helix, has welcomed yet another Newcastle University spin-out, who has developed and commercialised a prognostic test for early-stage skin cancer.

ARE YOU PREPARED FOR THE NEXT BIOHAZARD?

Biohazards are understandably in the spotlight again, due to COVID-19. As a health and safety consultancy specialising in the scientific sector, Bishop Simon Ltd was asked by the Institution of Occupational Safety and Health Magazine to contribute to their article “ARE YOU PREPARED FOR THE NEXT BIOHAZARD” - https://www.ioshmagazine.com/2020/09/09/are-you-prepared-next-biohazard. The article focuses on health and safety practices that organisations are applying to meet the challenges of outbreaks.

Meet Us At...

Below you'll find a list of events and conferences where One Nucleus will be in attendance. Feel free to reach out during these conferences to speak to our BD team.

We can offer a discount on registration, to our members, to many of the below. Get in touch here for discount codes.

Oncologica secures last available state of the art laboratory suite within the Newnham Building at Chesterford Research Park

Cambridge, UK, 05 October 2020: Chesterford Research Park is delighted to confirm that Oncologica has secured the last available suite within the newly re-configured Newnham building at the Park and will take up occupancy with immediate effect post partial practical completion, which is due within the next week.

My Account